Differential sensitivity of metabolically competent and non-competent HepaRG cells to apoptosis induced by diclofenac combined or not with TNF-alpha
Houssein Al-Attrache, Ahmad Sharanek, Audrey Burban, Matthew Burbank, Thomas Gicquel, Ziad Abdel-Razzak, Christiane Guguen-Guillouzo, Isabelle Morel, André Guillouzo

To cite this version:
Houssein Al-Attrache, Ahmad Sharanek, Audrey Burban, Matthew Burbank, Thomas Gicquel, et al.. Differential sensitivity of metabolically competent and non-competent HepaRG cells to apoptosis induced by diclofenac combined or not with TNF-alpha. Toxicology Letters, Elsevier, 2016, 258, pp.71–86. <10.1016/j.toxlet.2016.06.008>. <hal-01372855>
Differential sensitivity of metabolically competent and non-competent HepaRG cells to apoptosis induced by diclofenac combined or not with TNF-α

Houssein Al-Attrache a, b, d, Ahmad Sharanek a, b, Audrey Burban a, b, Matthew Burbank a, b, Thomas Gicquel a, b, c, Ziad Abdel-Razzak d, Christiane Guguen-Guillouzo a, b, Isabelle Morel a, b, c, André Guillouzo a, b

a Inserm U991, Faculty of Pharmacy, Rennes, France b Rennes 1 University, Rennes, France c Laboratory Emergency and Intensive Care, Hospital Pontchaillou, Rennes, France d Laboratory of Applied Biotechnology: biomolecules, biotherapy and bioprocesses (LBA3B), AZM Center-Tripoli and EDST-PRASE-Beirut, Rafic Hariri Campus—Lebanese University, Lebanon
HIGHLIGHTS

- HepaRG hepatocytes are less sensitive to DCF than HepG2 cells and undifferentiated HepaRG cells
- The lower sensitivity of HepaRG hepatocytes is related to their high detoxifying capacity
- Inhibition of glutathione transferases results in increased DCF cytotoxicity
- TNF-α potentiation of DCF cytotoxicity is not observed in undifferentiated HepaRG cells
- DCF-induced cholestasis typified by bile canaliculi dilatation is not aggravated by TNF-α
Abstract

The role of reactive metabolites and inflammatory stress has been largely evoked in idiosyncratic hepatotoxicity of diclofenac (DCF); however mechanisms remain poorly understood. We aimed to evaluate the influence of liver cell phenotype on the hepatotoxicity of DCF combined or not with TNF-α using differentiated and undifferentiated HepaRG cells, and for comparison, HepG2 cells. Our results demonstrate that after a 24h-treatment metabolizing HepaRG cells were less sensitive to DCF than their undifferentiated non-metabolizing counterparts as shown by lower oxidative and endoplasmic reticulum stress responses and lower activation of caspase 9. Differentiated HepaRG cells were also less sensitive than HepG2 cells. Their lower sensitivity to DCF was related to their high content in glutathione transferases. DCF-induced apoptotic effects were potentiated by TNF-α only in death receptor-expressing differentiated HepaRG and HepG2 cells and were associated with marked activation of caspase 8. TNF-α co-treatment did not aggravate DCF-induced cholestatic features. Altogether, our results demonstrate that (i) lower sensitivity to DCF of differentiated HepaRG cells compared to their non-metabolically active counterparts was related to their high detoxifying capacity, giving support to the higher sensitivity of nonhepatic tissues than liver to this drug; (ii) TNF-α-potentiation of DCF cytotoxicity occurred only in death receptor-expressing cells.
Abbreviations:

ABT, 1-Aminobenzotriazole; Ac-DEVD-AMC, N-Acetyl-Asp-Glu-Val-Asp-7-amido-4-methylcoumarin; AC-IETD-AMC, Ac-Ile-Glu-Thr-Asp-7-Amino-4-methylcoumarin; AC-LEHD-AMC, Ac-Leu-Glu-His-Asp-7-Amino-4-methylcoumarin; BSEP, bile salt export pump; CDF, 5 (and 6)-carboxy-2',7'-dichlorofluorescein (CDF); CRP, C-reactive protein; CYP450, cytochrome P450; DCF, diclofenac; DILI, drug-induced liver injury; ER, endoplasmic reticulum; H2-DCFDA, 2',7'-dichlorodihydrofluorescein; HO1, heme oxygenase 1; IL-8, interleukin-8; MnSOD, manganese superoxide dismutase; MRP2, multidrug associated protein 2; MTT, methylthiazolate tetrazolium; NAC, N-acetyl cysteine; NTCP, Na⁺ -dependent taurocholate cotransporting polypeptide; PBS, phosphate buffered saline; ROS, reactive oxygen species; RT-qPCR, real-time quantitative polymerase chain reaction; TNF-α, tumor necrosis factor α.

Keywords: Drug metabolism, differentiation status, tumor necrosis factor α, caspases, reactive oxygen species, endoplasmic reticulum stress, cholestasis, glutathione transferases, HepG2 cells, primary human hepatocytes.
1. Introduction

Drug-induced idiosyncratic hepatotoxicity represents 13-17% of all cases of acute liver failure (Bjornsson and Olsson, 2006). Formation of reactive metabolites, generation of oxidative stress, inflammatory stress and immune response are recognized to be potential critical determinants (Uetrecht, 2006).

Diclofenac (DCF) is a non-steroidal anti-inflammatory drug widely used for the treatment of rheumatoid arthritis, osteoarthritis and acute injury pain. Its administration has been associated with adverse effects in various organs, especially the gastrointestinal tract and kidney. DCF has also caused rare cases of hepatocellular injury, cholestasis or mixed hepatocellular injury and cholestasis (Banks et al., 1995; Breen et al., 1986; Watanabe et al., 2007). DCF-induced liver toxicity has been related to the formation of reactive metabolites, i.e. quinone imines from 4'-OH-DCF and 5-OH-DCF, and acyl glucuronides primarily catalyzed by UGT2B7 (Bort et al., 1999; Kretz-Rommel and Boelsterli, 1993; Wang et al., 2004). DCF-acyl glucuronides can bind selective proteins, including dipeptidyl peptidase IV, a canalicular membrane protein (Seitz and Boelsterli, 1998; Seitz et al., 1998). However, the role of these protein adducts in the pathogenesis of DCF-associated liver toxicity remains unclear (Aithal and Day, 2007; Banks et al., 1995).

DCF and its CYP-mediated metabolites 4'-OH-DCF and 5-OH-DCF induce concentration-dependent apoptosis at equimolar concentrations, the greatest pro-apoptotic activity being produced by 5-OH-DCF in primary human hepatocytes (Bort et al., 1999). However, DCF does not appear to be more cytotoxic to human hepatocytes than to HepG2 cells which usually express low drug metabolizing enzyme activities (Fredriksson et al., 2011; Gomez-Lechon et al., 2003b). Moreover, DCF has been
shown to be toxic to non-hepatic organs and cells at doses even lower than those required for liver toxicity (Ng et al., 2008). All these data make questionable the direct involvement of CYP-derived metabolites in DCF cytotoxicity \textit{in vivo} and \textit{in vitro}. DCF-induced apoptosis is strongly potentiated by TNF-α in HepG2 cells (Fredriksson et al., 2011; Maiuri et al., 2015) and lipopolysaccharide in rodent liver (Deng et al., 2006). The involvement of the intrinsic apoptotic pathway characterized by disruption of mitochondrial integrity has been demonstrated in various studies (Fredriksson et al., 2011; Gomez-Lechon et al., 2003a), and oxidative and endoplasmic reticulum (ER) stresses have been identified as independent cytotoxic responses to both DCF alone and the combination DCF/TNF-α (Fredriksson et al., 2014). The synergistic effect of DCF/TNF-α co-treatment appeared to occur mostly via activation of the extrinsic apoptotic pathway (Fredriksson et al., 2011).

In the present work, we further investigated mechanisms of DCF hepatotoxicity and cross-talk between hepatocyte apoptosis induced by DCF and TNF-α challenge using differentiated, metabolically competent and undifferentiated, non metabolically competent HepaRG cells and for comparison, HepG2 cells. At their undifferentiated stage HepaRG cells express markers of progenitors and do not exhibit detectable drug metabolizing enzyme activities; however, they can reach the capacity to express functions of mature hepatocytes, including CYP2C9 and CYP3A4 which are the main CYPs involved in the formation of CYP-mediated metabolites of DCF (Aninat et al., 2006; Guillouzo and Guguen-Guillouzo, 2008), as well as detoxifying enzymes (Aninat et al., 2006; Gerets et al., 2012; Rogue et al., 2012). We show here that sensitivity of liver cells to DCF-induced apoptosis was related to their phenotype and that potentiation by TNF-α was observed only in differentiated HepaRG cells expressing liver-specific functions and in HepG2 cells.
2. Materials and Methods

2.1. Chemicals and reagents

1-Aminobenzotriazole (ABT), diclofenac sodium salt (DCF), dithiothreitol (DTT), methylthiazoltetrazolium (MTT), N-acetyl-Asp-Glu-Val-Asp-7-amido-4-methylcoumarin (AC-DEVD-AMC), N-acetyl-cysteine (NAC), ethacrynic acid, 6β-hydroxy-testosterone and testosterone were purchased from Sigma Aldrich (St. Quentin Fallavier, France). 2′, 7′-Dichlorodihydrofluorescein (H2-DCFDA) was from Invitrogen Molecular Probe (Cergy-Pontoise, France). Ac-Ile-Glu-Thr-Asp-7-Amino-4-methylcoumarin (AC-IETD-AMC) and Ac-Leu-Glu-His-Asp-7-Amino-4-methylcoumarin (AC-LEHD-AMC) were supplied by Enzo Life Sciences (Lyon, France). TNF-α was provided by Promocell (Nuremberg, Germany). eIF2α (catalog 9722) and phospho-eIF2α (Ser51) (catalog 3597) were from Cell Signaling Technology (Danvers, MA, USA). CXCL8/IL-8 and Human C-reactive protein (CRP) DuoSet kits were from R&D (Abingdon, United Kingdom). N-benzyloxycarbonyl-Leu-Glu(OMe)-His-Asp(OMe)-fluoromethyl ketone (z-LEHD-fmk) was purchased from BD Biosciences (Le Pont de Claix, France) and etanercept was from Amgen (Thousand Oaks, CA, USA). Glutathione transferases (GST) A1/2 and M1/2 antibodies were gifts from Dr Caroline Aninat (Rennes).

2.2. Cell cultures and treatments

2.2.1. Cell cultures

HepaRG cells were seeded at a density of $2.6 \times 10^4$ cells/cm$^2$ in Williams’ E medium supplemented with 10 % Hyclone® fetal bovine serum (Thermo scientific, San Jose, USA), 100 U/mL penicillin, 100 μg/mL streptomycin, 5 μg/mL insulin, 2 mM glutamine, and 50 μM hydrocortisone hemisuccinate. After 2 weeks, these undifferentiated cells
were shifted to the same medium supplemented with 1.7% dimethyl sulfoxide (DMSO) for further 2 weeks in order to obtain cells expressing liver-specific functions. At that time, cultures contained hepatocyte-like and progenitors/primitive biliary-like cells in nearly equal proportions (Cerec et al., 2007).

HepG2 cells were seeded at a density of $2.6 \times 10^4$ cells/cm$^2$ in minimum essential medium-$α$ supplemented with 10 % Hyclone® fetal bovine serum, non-essential amino acids, 100 U/ml penicillin and 100 μg/ml streptomycin, and were used at subconfluence.

Primary human hepatocytes were obtained from Biopredic International (St Grégoire, France). They were isolated by collagenase-perfusion of liver biopsies from adult donors (Guguen-Guillouzo et al., 1982). These cells were cultured at a density of $1.5 \times 10^5$ /cm$^2$ in a Williams’ E medium containing 10 % Hyclone® fetal bovine serum without hydrocortisone hemisuccinate for the first 24h and in a medium deprived of serum and hydrocortisone thereafter. Cultures were used at day 4.

2.2.2. Treatments

All treatments were performed on cells maintained in a medium containing 2% Hyclone® fetal bovine serum and 0.2% DMSO (used as a vehicle). Selection of TNF-$α$ concentration (10ng/ml) was based on previous studies (Bachour-El Azzi et al., 2014; Fredriksson et al., 2014) and preliminary experiments on determination of caspase 3 activity and CRP secretion levels. However, except otherwise indicated a co-treatment with DCF and cytokine meant a pre-treatment with the cytokine alone before treatment with DCF/cytokine combination.

2.3. MTT assay
Cytotoxicity was evaluated using the MTT colorimetric assay. Briefly, cells were seeded in 24-well plates and treated with either TNF-α or various concentrations of DCF (50, 100, 150, 200, 250, 350 or 500 μM) after pre-treatment or not with TNF-α. After medium removal, 500 μl of serum-free medium containing MTT (0.5 mg/ml) was added to each well and incubated for 2h at 37°C. The water-insoluble formazan was dissolved in 500 μl DMSO and absorbance was measured at 550 nm (Aninat et al., 2006).

2.4. Phase-contrast imaging analysis

Cells were treated with DCF, TNF-α and DCF ± TNF-α for different times (0, 4 and 24h) and images were taken using a phase-contrast microscope (Inverted microscope Zeiss axiovert 200M and Axiocam MRm).

2.5. ELISA assays

C-reactive protein (CRP) and interleukin-8 (IL-8) proteins were measured in cell supernatants using CRP and CXCL8/IL-8 DuoSet kits, according to manufacturer’s instructions. Briefly, supernatants were collected after 24h treatment and stored at -80°C until analysis; 96-well microplates were coated with capture antibody and incubated overnight. Samples and standards were diluted appropriately and added for 2h after a saturation step. Secondary antibody was added for 2h after washing. Streptavidin-horseradish peroxidase and its substrate were used for the revelation step. Optical density was read at 450nm with wavelength correction. All steps were performed at room temperature (Bachour-El Azzi et al., 2014).

2.6. Determination of ROS generation
ROS generation was determined by the H$_2$-DCFDA assay. After treatment with DCF ± TNF-α for 30min, 2h, 4h, 8h and 24h, 10$^6$ cells were incubated for 2h at 37°C with 2μM H$_2$-DCFDA and then washed with cold PBS, and scraped in potassium buffer (10mM, pH 7.4)/methanol (v/v) complemented with Triton X-100 (0.1%). Fluorescence intensity of cell lysates was determined by spectrofluorimetry using excitation/emission wavelengths of 498/520 nm (Sharanek et al., 2014).

2.7. Determination of caspase 3, 8 and 9 activities

After treatment with DCF ± TNF-α, the cells were scraped in the culture medium, then centrifuged, washed with PBS, dried and stored at -80°C. Cell lysates were re-suspended in 70μl of 4-(2-hydroxyethyl)-1-piperazine ethane sulfonic acid supplemented with anti-phosphatase and anti-protease. Then, 40 μg proteins of each sample was placed in an opaque plate in triplicate and supplemented with caspase buffer (20 mM piperazine-1,4-bis-2-ethanesulfonic acid, pH 7.2, 100 mM NaCl, 10mM dithiothreitol, 1mM EDTA, 0.1% 3-[(3-cholamidopropyl)dimethylammonio]-1-propane sulfonic acid and 10% sucrose. Then 2 μl of DEVD-AMC, LEHD or IETD substrates for caspases 3, 9 and 8 respectively, was added. Fluorescence was measured at a wavelength between 380 and 420 nm for caspase 3 and between 405 and 465 nm for caspases 8 and 9 (Dumont et al., 2010; Maianski et al., 2004).

The influence of different inhibitors on caspase activities was also tested. The antioxidant N-acetyl cysteine (NAC) was added to cultures treated with DCF, TNF-α or their combination for 24h at the concentration of 5mM (Fredriksson et al., 2011; Sharanek et al., 2014; Son et al., 2013). Etanercept, a soluble p75 TNF-α receptor that prevents TNF-α to activate its membrane-bound receptor, thereby leading to inhibition of caspase 8 activation via the extrinsic apoptotic pathway (Jouan-Lanhouet et al.,
2012), and Z-LEHD-fmk, a specific inhibitor of caspase 9 activation (Maccarrone et al., 2000), were added at the concentrations of 10μg/ml and 20μM respectively, one hour before treatment with DCF and/or TNF-α.

2.8. Western blotting analysis

HepaRG cells were incubated in a medium added or not with DCF ± TNF-α for 2h after pre-treatment or not with the cytokine. P-eIF2α, eIF2α, GSTA1/2 and GSTM1/2 were analyzed according to methods previously described (Fredriksson et al., 2011; Zeng et al., 2014).

Briefly, after treatment, cells were washed with cold PBS and re-suspended in cell lysis buffer and a protease inhibitor cocktail. Aliquots containing an equivalent total protein content, as determined by the Bradford’s procedure with bovine serum albumin as the standard, were subjected to sodium dodecyl sulfate/4-12 % polyacrylamide gel electrophoresis, electrotransferred to immobilon-P membranes, and probed overnight with p-eIF2α, eIF2α or GST antibodies. After incubation with a rabbit secondary antibody, a chemiluminescence reagent, and Hyperfilm ECL, bands were quantified by densitometry with Fusion-Capt software (Marne-La vallée, France).

2.9. Measurement of CYP3A4 activity

After treatment with DCF ± TNF-α cells were washed with PBS and incubated at 37ºC with testosterone dissolved in Williams’E medium without phenol red. After 2h, medium was collected and CYP3A4 activity was measured using a high performance liquid chromatography equipment (Agilent 1100 series high performance liquid chromatograph equipped with an autosampler and Agilent 1100 series fluorescence and UV detectors) with two solvents, acetic acid (0.1%) and acetonitrile, as previously (Aninat et al., 2006).
2.10. *Diclofenac biokinetics*

Cultures were incubated with 200μM DCF ± TNF-α for 2, 4 and 24h; then cell supernatants and lysates were diluted 100 times in the mobile phase and analyzed by Liquid Chromatography - High Resolution - Mass Spectrometer (LC-HR-MS) Q ExactiveTM (Thermo Scientific). An HESI-II ion source was used for the electrospray ionization of target compounds. The chromatographic separation of the analytes was performed with an Accela pump (Thermo Scientific) equipped with a Thermo Fisher C18 Accucore column (100 x 2.1 mm , 2.6μM) using a gradient of 10 mM ammonium acetate buffer containing 0.1% (v/v) formic acid and of acetonitrile with 0.1% (v/v) formic acid. Retention times were respectively 1.6 min and 1.3 min for DCF and OH-DCF. Calibration curves were obtained by spiking mobile phase with standards at 0.01 to 10 μM. Data were acquired in negative Full Scan mode and quantification was performed by extracting the exact mass value of deprotonated DCF (294.0095 m/z) and OH-DCF (310.0042 m/z) using a 5 ppm mass window. 4-OH DCF and 5-OH DCF were not separated chromatographically; consequently OH-metabolites represented the sum of both.

2.11. *Real-Time Quantitative Polymerase Chain Reaction (RT-qPCR) analysis*

Total RNA was extracted from 10⁶ HepaRG or HepG2 cells with the SV total RNA isolation system (Promega, Charbonnieres-les-Bains, France). RNAs were reverse-transcribed into cDNA and RT-qPCR was performed using a SYBR Green mix. Primer sequences are listed in Supplementary Table 1.

2.12. *Taurocholic acid efflux*

To estimate bile salt export pump (BSEP) activity cells were first exposed to 43.3nM [³H]-taurocholic acid ([³H]-TA) for 30min, after washing cells were incubated with DCF
± TNFα in a standard buffer containing Ca²⁺ and Mg²⁺. After 2h incubation cells were washed and then scraped in 0.1N NaOH. The remaining radiolabeled substrate was measured through scintillation counting to determine TA efflux (Antherieu et al., 2013).

2.13. Na⁺-dependent taurocholate co-transporting polypeptide activity (NTCP)

NTCP activity was estimated by determination of sodium-dependent intracellular accumulation of [³H]-TA substrate. Cells were treated with DCF ± TNF-α followed by incubation with 43.3nM radiolabeled TA for 30min. Then, they were washed with standard buffer and lysed with 0.1N NaOH. Accumulation of radiolabeled substrate was determined through scintillation counting (Sharanek et al., 2015).

2.14. CDF efflux determination

After treatment with DCF ± TNF-α for 4h cells were incubated with 3µM of 5 (and 6)-carboxy-2,7-dichlorofluorescein diacetate (CDFDA) for 30min at 37 °C. Upon hydrolysis by intracellular esterases, CDFDA was converted to fluorescent CDF (excitation/emission: 488/509 nm) and directed towards the biliary pole by membrane transporters, particularly by the multidrug resistance-associated protein 2 (MRP2). After washing with phenol red-free Williams’ E medium. Imaging was performed using a Cellomics ArrayScan VTI HCS Reader (Thermo Scientific) (Bachour-El Azzi et al., 2015).

2.15. Statistical analysis

One-way ANOVA with Bonferroni’s multiple comparison test (GraphPad Prism 5.00) was performed to compare data between DCF-, TNF-α-, DCF + TNF-α-treated cells and control cultures. Each value corresponded to the mean ± standard error of the mean (SEM) of three independent experiments. Data were considered significantly different when p < 0.05.
3. Results

3.1. Differential sensitivity of metabolically and non metabolically competent HepaRG cells to DCF

DCF cytotoxicity was first estimated using the MTT assay after a 24h treatment. A decrease in cell viability was observed in a dose-dependent manner with drug concentrations starting at 350μM (IC50≈780μM) in differentiated HepaRG cells. Human hepatocytes obtained from three donors showed similar sensitivity to DCF toxicity (IC50≈800μM) as differentiated HepaRG cells. Undifferentiated HepaRG (8 days after seeding) and subconfluent HepG2 cells were more sensitive (IC50s = 468 and 688 μM respectively) (Figure 1A-D).

Apoptotic effects of DCF were also estimated by determination of caspase 3 activity. A 1.8-fold augmentation was observed in differentiated HepaRG cells treated with 200μM DCF. Interestingly, undifferentiated HepaRG and subconfluent HepG2 cells were respectively 3- and 2-fold more sensitive to DCF than differentiated HepaRG cells exposed to 200μM DCF (Fig. 1E and F).

Accordingly, cell examination under phase-contrast microscopy after a 24h treatment evidenced some cell detachment in undifferentiated HepaRG and HepG2 cell cultures exposed to 200μM DCF (Fig. 2).

To confirm the lower sensitivity of HepaRG hepatocytes compared to primitive biliary cells, cultures containing 80% HepaRG hepatocytes (instead of 50%) were prepared by cell seeding at high density (Pernelle et al., 2011). In such cultures sensitivity to DCF was further reduced, not exceeding 2.9-fold (versus 5.8-fold) with 350μM (data not shown). Based on all these results, DCF was usually used at 200μM for further investigations.
3.2. **Diclofenac metabolizing capacity of HepaRG and HepG2 cells**

Drug metabolism capacity of differentiated cells was first evaluated by determination of CYP3A4 activity and transcript levels. CYP3A4 is the main expressed CYP gene in mature hepatocytes and is involved in DCF metabolism (Shen et al., 1999; Tang et al., 1999). As expected, high levels of transcripts and activity were measured in differentiated HepaRG cells; they were not significantly modulated by 200 μM DCF (Fig. 3A and B).

Then, in order to determine whether DCF was metabolized by differentiated HepaRG cells, undifferentiated HepaRG cells and HepG2 cells, its biokinetics was estimated over a 24h period. DCF and OH-metabolites were measured in both media and cell lysates after 2, 4 and 24h. In differentiated HepaRG cells, the percentage of unchanged DCF recovered in medium and cell layers decreased with time and represented only 14% of the initial 200 μM DCF concentration after 24h. In parallel, increasing production of OH-metabolites was evidenced (Fig. 3C-F). DCF and/or OH-metabolites did not accumulate intracellularly. Formation of OH-metabolites was completely prevented by co-addition of 300 μM 1-aminobenzotriazole (ABT), a non selective inhibitor for human P450s. By contrast, no obvious loss of DCF was evidenced in undifferentiated HepaRG cells (data not shown) and in HepG2 cells after 24h-exposure (Supplementary Fig. 1). All these data supported the conclusion that undifferentiated HepaRG and HepG2 cells had low DCF metabolism capacity if any.

3.3. **Only differentiated HepaRG and HepG2 cells are responsive to TNF-α**

First, differentiated HepaRG cells were exposed to 10ng/ml TNF-α and their responsiveness was estimated by determination of CRP and IL-8 transcripts levels and protein secretion rate. CRP and IL-8 secretion levels were measured in the medium of
untreated and DCF-treated cells in the absence or presence of TNF-α for 24h using ELISA assays. Untreated cells secreted 26 ± 4 pg/ml CRP and 21 ± 5 pg/ml IL-8, and a 37 and 31% decrease in the release of CRP and IL-8 respectively was evidenced after treatment with 200μM DCF alone, compared to untreated cells. TNF-α strongly increased secretion levels of these two inflammatory markers (12.6- and 41.7-fold for CRP and IL-8 respectively) while a co-treatment with DCF resulted in lower increases (6.1- and 23.3-fold for CRP and IL-8 respectively compared to untreated cells) (Supplementary Fig. 2A and B). All these results were confirmed at mRNA levels by PCR analysis. Co-treatments with 200μM DCF also resulted in lower increase of both protein and transcripts levels (Supplementary Fig. 2C and D).

Then, the influence of TNF-α on DCF cytotoxicity was evaluated using the MTT and caspase 3 activity assays. When differentiated HepaRG cells were exposed to TNF-α for 24h before co-exposure to the drug for further 24h, cytotoxicity was not aggravated in differentiated HepaRG cells using the MTT assay (Fig. 1A) and human hepatocytes (Fig. 1D). However, a significant increase in caspase 3 activity was observed with 200μM DCF in combination with TNF-α (5.24-fold vs TNF-α alone) in differentiated cells after pre-treatment with the cytokine (Fig. 1E) while no change and only a slight increase were observed in undifferentiated HepaRG cells and HepG2 cells respectively (Fig. 1E and F). However, treatment with 250μM DCF + TNF-α hugely activated caspase 3 (around 15-fold) in these latter (Fig. 1F).

Since pro-inflammatory cytokines are known to inhibit the major CYPs involved in drug metabolism (Abdel-Razzak et al., 1993), we then investigated whether a pre-treatment with TNF-α could modulate activity and expression of CYP3A4 in differentiated HepaRG cells treated with 200μM. Whereas CYP3A4 activity was not significantly modulated by DCF alone, it decreased to 44% with TNF-α and 34% with TNF-α + DCF.
(Fig. 3A). CYP3A4 transcript levels dropped by 54% and 85% of the control values with TNF-α alone and TNF-α + DCF, respectively (Fig. 3B). Of note, transcripts of CYP2C9, the other CYP involved in DCF metabolism (Shen et al., 1999), were similarly reduced by DCF, TNF-α and co-treatments (Data not shown).

DCF biokinetics and OH-metabolites formation were also measured in cultures of differentiated HepaRG cells co-treated with 200μM DCF and TNF-α over a 24h period. A limited decrease in DCF disappearance was observed with TNF-α + DCF (27%) compared to DCF alone (14%). Accordingly, a slight decrease in the formation of OH-metabolites was observed with TNF-α + DCF (22%) compared to DCF alone (28%). Noteworthy, ABT decreased DCF disappearance to 57% and completely inhibited OH-metabolites formation (Fig. 3C-G). As found with DCF alone no obvious loss of DCF and formation of OH-metabolites were evidenced in undifferentiated HepaRG (data not shown) and HepG2 cells after treatment with the combination DCF + TNF-α (Supplementary Fig. 1).

3.4. **DCF-induced generation of oxidative stress**

Treatment of differentiated HepaRG cells with DCF alone did not induce generation of detectable oxidative stress at concentrations up to 200μM, even after 24h as shown by measurement of reactive oxidative species (ROS) using the DCFDA assay. However, a first treatment with TNF-α followed by co-treatment with 200μM DCF caused a slight generation of ROS within the first 8h which reached 3.5-fold after 24h (Fig. 4A). Transcript levels of the two oxidative stress-related genes HO-1 and MnSOD were also slightly augmented in differentiated HepaRG cells, i.e. 1.4- and 1.5-fold, after treatment with 200μM DCF and 1.6- and 2-fold after co-treatment with DCF + TNF-α respectively after 24h (Fig. 4B and C).
A slight production of ROS was detected in undifferentiated HepaRG cells during the first 8h after treatment with 200μM DCF (1.4-fold); this production reached 2.8-fold after 24h (Fig. 4D). Noticeably, HO-1 and MnSOD gene expression was also augmented in undifferentiated HepaRG cells exposed to DCF alone (3.6- and 3.1-fold respectively) and slightly more after co-treatment with DCF + TNF-α, reaching 3.9- and 3.3-fold for HO-1 and MnSOD respectively (Fig. 4E and F).

In addition, ROS generation was measured in the presence of NAC, z-LEHD-fmk and etanercept. A high inhibition of ROS generation was observed in the presence of NAC in undifferentiated HepaRG cells treated with DCF alone, and in differentiated HepaRG cells treated with DCF + TNF-α, and in the presence of etanercept in co-treated differentiated HepaRG cells. Z-LEHD-fmk exerted only a slight inhibition of ROS production (Supplementary Fig. 3A and B).

3.5. **Enhancement of DCF-induced ER stress by TNF-α in differentiated cells**

A specific activation of the ER stress route through the ATF4 transcriptional activity has also been reported in DCF-treated liver cells (Fredriksson et al., 2014). Our results showed that transcripts levels of ATF4, ATF6, CHOP and GRP78 were all overexpressed in differentiated HepaRG cells exposed to 200μM DCF for 24h. The increases were significant with 200μM for the 4 genes and co-treatment with TNF-α led to a further significant increase. CHOP was more up-regulated than ATF4 and ATF6 (Fig. 5A-D).

These 4 genes were more responsive to DCF in undifferentiated HepaRG cells; they were already overexpressed with 50μM and their increase reached values between 3.5-fold (ATF4, ATF6 and GRP78) and 5-fold (CHOP) with 200μM. Co-treatment with TNF-α did not further enhance expression of these 4 genes (Fig. 5E-H).
Phosphorylation of eIF2α, the upstream regulator of CHOP and ATF4 (Oslowski and Urano, 2011), was also analyzed by western blotting after 2h of treatment. While it had no obvious effect in differentiated HepaRG cells, the combination TNF-α + DCF increased p-eIF2 in undifferentiated HepaRG cells compared to DCF-treated cells (Fig. 6A and B).

### 3.6. Modulation of caspases 8, 9 and 3 activities by DCF and TNF-α

We further analyzed whether DCF ± TNF-α altered activity of the two initiator caspases 8 and 9. DCF alone increased nearly 2-fold more caspase 9 than caspase 8 (3.1-versus 1.7-fold) in differentiated cells and more strongly both caspases in undifferentiated cells (5.4- and 2.4-fold caspases 9 and 8 respectively). As expected, compared to DCF alone co-treatment with TNF-α strongly enhanced caspase 8 in differentiated cells and only slightly in their undifferentiated counterparts. Caspase 9 was slightly enhanced if any in both differentiated and undifferentiated cells by co-treatment (Fig. 7A-D).

To confirm the involvement of caspase 3, 8 and 9 in DCF +/- TNF-α toxicity, cells were co-treated with different inhibitors, i.e. NAC, z-LEHD-fmk and etanercept. In DCF-treated differentiated HepaRG cells the slight increase of caspase 8 was nearly completely abolished by NAC and z-LEHD-fmk, and caspase 9 activation was also strongly reduced by these two inhibitors (i.e. 66.7 and 94.8% respectively) (Fig. 7C). Additional caspase 8 activation by DCF + TNF-α co-treatment was mostly abolished (85%) in the presence of etanercept. NAC and z-LEHD-fmk also strongly inhibited caspases 8 and 9 in DCF-treated undifferentiated HepaRG cells reaching 86 and 87.9% for the former and 65.3 and 95.9% for the latter respectively. As expected, addition of etanercept was without any effect (Fig. 7B and C). The effects of the
different inhibitors in HepG2 cells treated with DCF or DCF + TNF-α were comparable to those observed in differentiated HepaRG cells treated in similar conditions (Supplementary Fig. 5). Activation of caspase 3 by DCF and DCF + TNF-α reflected changes in caspases 9 and/or 8 in the three cell models (Supplementary Fig. 4).

### 3.7. Sensitivity to DCF is inversely correlated to GST content

Several studies have demonstrated that GSTs play a key role in detoxifying processes (Board and Menon, 2013). We have analyzed GST A1/2 and M1/2 content in both differentiated and undifferentiated HepaRG cells, and in HepG2 cells. As shown in Fig. 8 both GSTs were less abundant in undifferentiated HepaRG cells (72.6 and 59.8% less for A1/2 and M1/2 respectively) and in HepG2 cells (35.6 and 17.51% less for A1/2 and M1/2 respectively) than in differentiated HepaRG cells (Fig. 8A-D).

Similarly, co-treatment of differentiated HepaRG cells with DCF + TNF-α caused a decrease in transcript levels of the two GST isoforms (35.5 , and 37.2% for GST A1/2 and GST M1/2 respectively), compared to treatment with DCF alone (Fig. 8E and F). Moreover, to confirm the protective role of GSTs against DCF cytotoxicity differentiated HepaRG cells were co-exposed to 10μM ethacrynic acid, a GST inhibitor (Awasthi et al., 1993), for 24h before determination of caspase 3 activity. As expected, DCF cytotoxicity was significantly enhanced (Fig. 9).

### 3.8. DCF-induced cholestatic features are not influenced by co-treatment with TNF-α

To determine whether DCF induced cholestatic effects in the presence or absence of TNF-α, differentiated HepaRG cells were regularly examined under phase-contrast microscopy following DCF ± TNF-α addition. Dilatation of many bile canaliculi was
observed after 6h with 50μM DCF (data not shown). Dilatations appeared as early as 1h treatment with 100 and 200μM DCF (Fig. 10A). TNF-α alone had no effect and did not potentiate bile canaliculi deformations caused by DCF (Fig. 10A).

To look for whether DCF-induced bile canaliculi deformations were associated with alterations of bile acids transport, activities of NTCP and BSEP were measured using [3H]-taurocholic acid as substrate. NTCP activity was slightly reduced after 24h treatment with 200μM DCF whereas it was strongly inhibited by TNF-α alone (Fig. 10B). By contrast, a dose-dependent augmentation of BSEP activity was evidenced with DCF alone without any further significant change by co-treatment with TNF-α after 2h (Supplementary Fig. 6). Both NTCP and BSEP transcripts were decreased by DCF and more extensively by co-treatment with TNF-α after 24h. Noticeably, CDF accumulated in dilatated bile canaliculi of DCF-treated cells (Fig. 10A).

4. Discussion

Formation of reactive CYP-mediated 4’OH- and 5’OH-metabolites and/or acyl glucuronides from DCF has been associated with induction of intrinsic apoptosis resulting from ROS generation and alteration of the mitochondrial function both in rat and human hepatocytes (Gomez-Lechon et al., 2003a; Masubuchi et al., 2002) and in HepG2 cells (Fredriksson et al., 2014). In the current study, we demonstrated that DCF caused cytotoxicity in the absence of any biotransformation by comparing metabolically and non-metabolically competent HepaRG cells. Indeed, undifferentiated HepaRG cells as well as HepG2 cells which exhibited low CYP activity if any, and did not form DCF-OH metabolites were more sensitive to the drug than HepaRG hepatocytes. The capacity of differentiated HepaRG cells to actively metabolize DCF
was verified by biokinetics analysis showing that drug disappearance was associated with formation of OH-metabolites.

Accordingly, primitive biliary cells were also found to be more sensitive than HepaRG hepatocytes to DCF in differentiated HepaRG cell cultures, further supporting that DCF could induce cytotoxicity in the absence of any metabolism. Moreover, sensitivity to DCF was found to be further reduced in differentiated HepaRG cell cultures when the percentage of HepaRG hepatocytes increased from 50 to 80%. The higher sensitivity of non-metabolically competent liver cells could be related to the capability of DCF to induce toxicity in several organs and non-hepatic cells. Indeed, DCF is also a powerful nephrotoxicant. DCF treatments have been associated with a number of cases of acute renal failure in humans (Rubio Garcia and Tellez Molina, 1992); they have also been shown to cause marked nephrotoxic effects in mouse in absence of evidence of any liver damage determined by serum alanine transaminase measurements, indicating that contribution of DCF metabolism and its consequences in the liver were not confounding factors towards culminating nephrotoxicity (Hickey et al., 2001). In agreement, the 250μM EC50 value reported with DCF-treated kidney LLC-PK1 pig cells (Ng et al., 2008) was lower than the value obtained with differentiated HepaRG cells (780μM, this study). Similarly, DCF-induced intestinal toxicity was recently found to be unrelated to its metabolism using precision-cut human intestinal slices (Niu et al., 2015). Noteworthy, while 70% of the patients receiving DCF therapy developed intestinal adverse effects (Zhu and Zhang, 2012) the risk of liver injury reached only 6 per 100000 users with chronic DCF administration (de Abajo et al., 2004).

DCF induced an apoptotic response in both differentiated and undifferentiated HepaRG cell models at lower concentrations than necrosis, as shown by using caspase 3 activation and MTT assays, in agreement with previous studies using other
liver cell models (Fredriksson et al., 2011; Gomez-Lechon et al., 2003b). The higher apoptotic response of non-metabolically competent liver cells to DCF was associated with generation of more reactive oxygen species, higher expression of the two oxidative stress-related genes HO1 and MnSOD and ER-stress-related genes, and higher activation of caspases 8, 9 and 3. Apoptosis can occur via two pathways: the intrinsic resulting from mitochondrial dysfunction and the extrinsic resulting from activation of external death receptors. It has been proposed that DCF-induced apoptosis is mainly mediated by the mitochondrial pathway, which involved generation of ROS and ER stresses, induction of the mitochondrial pore transition and activation of JNK (Fredriksson et al., 2014; Gomez-Lechon et al., 2003a; Masubuchi et al., 2002). In support, it has been shown that DCF could act as an uncoupler of oxidative phosphorylation in mitochondria (LoGuidice et al., 2012; Somasundaram, 2001). Our results agree with these conclusions. Indeed, co-treatments of DCF with the antioxidant NAC or the caspase 9 inhibitor z-LEHD-fmk largely prevented caspases 9 and 3 activation, suggesting that oxidative and ER stresses mediating mitochondrial pore transition were crucial events in DCF-induced apoptosis in differentiated and undifferentiated HepaRG cells. Similarly, DCF activation of these different caspases in HepG2 cells was also strongly reduced with NAC and z-LEHD-fmk, further supporting the prominent involvement of the intrinsic pathway as previously reported (Masubuchi et al., 2002).

Pro-inflammatory cytokines are known to severely enhance liver injury induced by various xenobiotics including DCF (Ramm and Mally, 2013). We showed here that TNF-α potentiated DCF toxicity in differentiated HepaRG cells, mainly through activation of caspases 8 and 3. Similar results, although to a lower extent, were obtained with HepG2 cells while undifferentiated HepaRG cells were nearly
unresponsive. The higher apoptotic response previously reported in HepG2 cells co-treated with DCF+TNF-α could likely be explained by the use of higher DCF concentrations (250-500μM) (Fredriksson et al., 2011). Activation of caspase 8 in co-treated differentiated HepaRG cells and HepG2 cells was mostly inhibited by etanercept, supporting the involvement of the extrinsic apoptotic pathway in potentiation of DCF cytotoxicity by TNF-α. Of note, the two TNF-α receptors (R1 and R2) were well expressed in these cells while they were barely detectable in undifferentiated HepaRG cells, thus explaining the unresponsiveness of these latter to TNF-α when combined with DCF (Supplementary Table 2).

Differentiated HepaRG cells contain large amounts of detoxifying enzymes (Aninat et al., 2006; Gerets et al., 2012; Rogue et al., 2012), that could contribute to inactivation of DCF reactive metabolites and protection against apoptotic effects of the drug. DCF quinone imine metabolites have been shown to be reduced by NAD(P)H:quinone oxido-reductase1 and conjugated to GSH by GSTs (Dragovic et al., 2013; Vredenburg et al., 2014). Our data confirming that differentiated HepaRG cells contained higher levels of GST A1/2 and M1/2 than their undifferentiated counterparts and HepG2 cells and showing their higher sensitivity to DCF following GST inhibition by ethacrynic acid, brought further support to their lower sensitivity to apoptotic effects of DCF. Moreover, the higher sensitivity of differentiated HepaRG cells to apoptotic effects of DCF following pre-exposure to TNF-α, which is associated with inhibition of CYPs and GSTs, as well as the comparable sensitivity of primary human hepatocytes and differentiated HepaRG cells to DCF supported our conclusions. Noticeably, a lower sensitivity of differentiated HepaRG cells compared to HepG2 cells has previously been reported for several known hepatotoxic chemicals (Gerets et al., 2012). Accordingly, the differential sensitivity of differentiated HepaRG cells and HepG2 cells
to DCF could be related to differences in both oxidative metabolism and detoxifying and antioxidant capacities. However, it cannot be excluded that GSTs were partly acting via their anti-apoptotic properties (Board and Menon, 2013; Gilot et al., 2002). Likelihood, its high content in GSTs and other detoxifying enzymes could also at least partly explain the lower sensitivity to DCF of the liver compared to other tissues. Besides its capacity to induce hepatocellular injury DCF can also cause cholestasis in humans. As observed with several other cholestatic drugs (Sharanek et al., 2016), we found that DCF provoked early dilatation of bile canaliculi at lower concentrations than those causing cytotoxicity and these bile canaliculi deformations were associated with alterations of taurocholic acid clearance as well as of expression of influx and efflux bile acid transporters. Although TNF-α did not obviously alter these major DCF cholestatic effects when added prior to and/or simultaneously with the drug this did not exclude that this cytokine could modulate bile acids synthesis and/or secretion. Altogether our results bring new insights in DCF-induced cytotoxicity and its potentiation by TNF-α. They demonstrate that DCF toxicity to human liver cells can occur in absence of biotransformation and through the intrinsic apoptotic pathway, and be related to the phenotype while its potentiation by TNF-α can be observed only in cells expressing death receptors and involves the extrinsic pathway. The lower sensitivity of human HepaRG hepatocytes to DCF-induced apoptosis can be explained by their high content in glutathione transferases and consequently by their ability to inactivate DCF reactive metabolites.

Financial support

This work was supported by the European Community [Contract MIP-DILI-115336]. The MIP-DILI project has received support from the Innovative Medicines Initiative

Houssein Al-Attrache was financially supported by the Association AZM-Lebanese University and the MIP-DILI project; Ahmad Sharanek by the Lebanese Association for Scientific Research (LASeR) and the MIP-DILI project, Audrey Burban by the MIP-DILI project and Matthew Burbank by a CIFRE contract with Servier.

**Disclosures:** The authors declare that there are no conflicts of interest.
References


the impairment of bile canalicular dynamics induced by cholestatic drugs. Sci Rep 6, 24709.


Uetrecht, J., 2006. Evaluation of which reactive metabolite, if any, is responsible for a specific idiosyncratic reaction. Drug Metab Rev 38, 745-753.


**Figure legends**

**Fig. 1. Influence of TNF-α on DCF-induced toxicity in differentiated and undifferentiated HepaRG cells, HepG2 cells and primary human hepatocytes.**

Cells were treated with diclofenac (DCF) ± TNF-α following pre-treatment or not with the cytokine. (A-D) MTT assay in the four cell models and (E) Caspase 3 activity in differentiated and undifferentiated HepaRG cells after treatment with DCF ± TNF-α. (F) Caspase 3 activity in HepG2 cells after the same treatments as in (E). All results are expressed relative to the levels found in corresponding untreated cells, arbitrarily set at a value of 1 or 100. *P<0.05, **P<0.01 and ***P<0.001 compared with untreated cells, #P<0.05 and ###P<0.001 compared with cells treated with TNF-α or DCF individually.

**Fig. 2. Effects of DCF and TNF-α on morphology of differentiated HepaRG, undifferentiated HepaRG and HepG2 cells**

Phase-contrast microscopy examination of differentiated HepaRG, undifferentiated HepaRG and HepG2 cells after treatment with TNF-α for 24h followed by 24h co-treatment with 200μM DCF ± TNF-α. White arrows demonstrate cell alterations characterized by cell detachment.

**Fig. 3. Effects of DCF and TNF-α on CYP3A4 activity and transcript levels and analysis of DCF biokinetics**

Differentiated HepaRG cells were exposed to DCF ± TNF-α. (A) CYP3A4 activity determined by HPLC and (B) CYP mRNA levels measured by RT-PCR analysis. Unchanged DCF and OH-metabolites were measured by LC-HR-MS in both
supernatants (C and D) and cell layers (E and F) after treatment with DCF alone or the combination DCF+TNF-α in differentiated HepaRG cells. Results in (A) and (B) are expressed relative to the levels found in control cells, arbitrarily set at a value of 100 or 1. Results in (C-F) are expressed relative to the levels found in unexposed media containing 200μM DCF, arbitrarily set at a value of 100. *P<0.05 and ***P<0.001 compared with untreated cells, ###P<0.001 compared with cells treated with TNF-α and DCF individually.

**Fig. 4. Effects of DCF±TNF-α on ROS generation and expression of HO-1 and MnSOD genes in differentiated and undifferentiated HepaRG cells**

Following exposure of cells to DCF ± TNF-α ROS generation was measured after 30min, 2h, 4h, 8h and 24h, using the H₂DCFDA assay and HO-1 and MnSOD transcripts levels were determined by RT-PCR analysis in (A, B and C) differentiated and (D, E and F) undifferentiated HepaRG cells. H₂O₂ (25 mM) was used as positive control after 2h treatment. All results are expressed relative to the levels found in control cells, arbitrarily set at a value of 1. *P<0.05, **P<0.01 and ***P<0.001 compared with untreated cells, ###P<0.001 compared with cells treated with TNF-α and DCF individually.

**Fig. 5. Transcript levels of ER stress genes after treatment with DCF ± TNF-α.**

ATF4, ATF6, CHOP and GRP78 gene expression was measured in differentiated (A, B, C and D) and undifferentiated HepaRG cells (E, F, G and H). All results are expressed relative to the corresponding levels found in control cells, arbitrarily set at a value of 1. **P<0.01 and ***P<0.001 compared with untreated cells, #P<0.05 and ###P<0.001 compared with cells treated with TNF-α and DCF individually.
Fig. 6. Western blotting analysis of p-elf2α in differentiated and undifferentiated HepaRG cells after exposure to DCF ± TNF-α.

Western blots (A) and quantification by densitometry (B) of p-elf2α content in differentiated and undifferentiated HepaRG cells after 2h treatment. Results are expressed relative to the levels found in control cells, arbitrarily set at a value of 1.

Fig. 7. Effects of inhibitors on caspases 8 and 9 activities in HepaRG cells exposed to DCF ± TNF-α.

NAC, etanercept and z-LEHD-fmk were added individually. A and C correspond to differentiated HepaRG cells and B and D to undifferentiated HepaRG cells. All results are expressed relative to the levels found in control cells, arbitrarily set at a value of 1. *P<0.05, **P<0.01 and ***P<0.001 compared with untreated cells, ##P<0.01 and ###P<0.001 compared with cells treated with TNF-α and DCF ± TNF-α individually without co-addition of inhibitors.

Fig. 8. Analysis of glutathione transferases (GSTs) in differentiated and undifferentiated HepaRG and HepG2 cells after exposure to DCF ± TNF-α.

Western blots and their quantifications: (A and C) GSTA1/2 and (B and D) M1/2 in differentiated and undifferentiated HepaRG cells and in HepG2 cells. HSC-70 was used as a loading control. (E and F) measurement of GSTA1/2 and GSTM1/2 genes expression in differentiated HepaRG cells after treatment with DCF ± TNF-α. Results in (C and D) are expressed relative to the levels found in differentiated HepaRG cells, arbitrarily set at a value of 100. Results in (E and F) are expressed relative to the levels found in control cells, arbitrarily set at a value of 1. *P<0.05, **P<0.01 and ***P<0.001 compared with untreated cells, ###P<0.001 compared with cells treated with TNF-α and DCF ± TNF-α individually without co-addition of inhibitors.
**Fig. 9. Effects of ethacrynic acid on caspase 3 activity in differentiated HepaRG cells.**

Cells were treated with DCF ± TNF-α in the presence or absence of 10μM ethacrynic acid for 24h before determination of caspase 3 activity. All results are expressed relative to the levels found in control cells, arbitrarily set at a value of 1. *P<0.05 and ***P<0.001 compared with untreated cells, ##P<0.01 and ###P<0.001 compared with cells treated with TNF-α and DCF individually. $P<0.05 and $$P<0.01 compared with cells unexposed to ethacrynic acid.

**Fig. 10. Effects of DCF±TNF-α on bile canaliculi morphology, DCF accumulation and NTCP activity in differentiated HepaRG cells.**

(A) Phase-contrast microscopy images showing bile canaliculi and intracanicular accumulation of fluorescent CDF after 4 and 24h of treatment (DCF at 200μM). (B) NTCP activity after 24h. White arrow shows dilatation of bile canaliculi. Results on NTCP activity are expressed relative to the levels found in control cells, arbitrarily set at a value of 1. ***P<0.001 compared with untreated cells.
Figure 1

(A) Differentiated HepaRG cells

(B) Undifferentiated HepaRG cells

(C) HepG2 cells

(D) Primary human hepatocytes

(E) HepaRG cells

(F) HepG2 Cells
Figure 2

Differentiated HepaRG cells (24h)

Untreated cells  DCF  TNF-α  DCF + TNF-α

Undifferentiated HepaRG cells (24h)

HepG2 cells (24h)
Figure 3

A

CYP2A4 activity (% of control)

B

CYP2A4 mRNA (fold change)

C

Unchanged DCF (% of initial DCF)

D

OH-DCF (% of initial DCF)

E

Unchanged DCF (% of initial DCF)

F

OH-DCF (% of initial DCF)
Figure 4

A. Differentiated HepaRG cells

B. HO-1 mRNA (Fold change)

C. MnSOD mRNA (Fold change)

D. Undifferentiated HepaRG cells

E. HO-1 mRNA (Fold change)

F. MnSOD mRNA (Fold change)
Figure 6

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**

A

B

**Figure 6**
Figure 8
Figure 9

Differentiated HepaRG cells

- without ethacrynic acid
- with ethacrynic acid

Caspase 3 activity (Fold change)

Control  |  DCF  |  TNF-α  |  DCF+TNF-α

Bar charts showing the caspase 3 activity for different conditions.
Figure 10

A

Phase-contrast (4h)

CDF (4h)

B

NTCP activity (Fold change)